Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study

Colin R Simpson, Nazir I Lone, Kimberley Kavanagh, Chris Robertson, Jim McMenamin, Beatrix von Wissmann, Eleftheria Vasileiou, Chris Butler, Lewis D Ritchie, Rory Gunson, Jürgen Schwarze, Aziz Sheikh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

INTRODUCTION: Seasonal (inactivated) influenza vaccination is recommended for all individuals aged 65+ and in individuals under 65 who are at an increased risk of complications of influenza infection, for example, people with asthma. Live attenuated influenza vaccine (LAIV) was recommended for children as they are thought to be responsible for much of the transmission of influenza to the populations at risk of serious complications from influenza. A phased roll-out of the LAIV pilot programme began in 2013/2014. There is limited evidence for vaccine effectiveness (VE) in the populations targeted for influenza vaccination. The aim of this study is to examine the safety and effectiveness of the live attenuated seasonal influenza vaccine programme in children and the inactivated seasonal influenza vaccination programme among different age and at-risk groups of people.

METHODS AND ANALYSIS: Test negative and cohort study designs will be used to estimate VE. A primary care database covering 1.25 million people in Scotland for the period 2000/2001 to 2015/2016 will be linked to the Scottish Immunisation Recall Service (SIRS), Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register. Vaccination status (including LAIV uptake) will be determined from the primary care and SIRS database. The primary outcome will be influenza-positive real-time PCR tests carried out in sentinel general practices and other healthcare settings. Secondary outcomes include influenza-like illness and asthma-related general practice consultations, hospitalisations and death. An instrumental variable analysis will be carried out to account for confounding. Self-controlled study designs will be used to estimate the risk of adverse events associated with influenza vaccination.

ETHICS AND DISSEMINATION: We obtained approval from the National Research Ethics Service Committee, West Midlands-Edgbaston. The study findings will be presented at international conferences and published in peer-reviewed journals.

TRIAL REGISTRATION NUMBER: ISRCTN88072400; Pre-results.

LanguageEnglish
Article numbere014200
Number of pages8
JournalBMJ Open
Volume7
Issue number2
DOIs
Publication statusPublished - 1 Feb 2017

Fingerprint

Human Influenza
Vaccination
Safety
Influenza Vaccines
Attenuated Vaccines
Scotland
Databases
General Practice
Immunization
Primary Health Care
Vaccines
Asthma
Virology
Research Ethics Committees
Health Services
Real-Time Polymerase Chain Reaction
Hospitalization
Cohort Studies
Referral and Consultation
Delivery of Health Care

Keywords

  • live vaccines
  • attenuated vaccines
  • inactivated vaccines
  • influenza
  • vaccination
  • seasonal
  • effectiveness
  • safety

Cite this

Simpson, Colin R ; Lone, Nazir I ; Kavanagh, Kimberley ; Robertson, Chris ; McMenamin, Jim ; von Wissmann, Beatrix ; Vasileiou, Eleftheria ; Butler, Chris ; Ritchie, Lewis D ; Gunson, Rory ; Schwarze, Jürgen ; Sheikh, Aziz. / Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination : protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. In: BMJ Open. 2017 ; Vol. 7, No. 2.
@article{fa2cc322c1e9459f8e8ff44f2919bc03,
title = "Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study",
abstract = "INTRODUCTION: Seasonal (inactivated) influenza vaccination is recommended for all individuals aged 65+ and in individuals under 65 who are at an increased risk of complications of influenza infection, for example, people with asthma. Live attenuated influenza vaccine (LAIV) was recommended for children as they are thought to be responsible for much of the transmission of influenza to the populations at risk of serious complications from influenza. A phased roll-out of the LAIV pilot programme began in 2013/2014. There is limited evidence for vaccine effectiveness (VE) in the populations targeted for influenza vaccination. The aim of this study is to examine the safety and effectiveness of the live attenuated seasonal influenza vaccine programme in children and the inactivated seasonal influenza vaccination programme among different age and at-risk groups of people.METHODS AND ANALYSIS: Test negative and cohort study designs will be used to estimate VE. A primary care database covering 1.25 million people in Scotland for the period 2000/2001 to 2015/2016 will be linked to the Scottish Immunisation Recall Service (SIRS), Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register. Vaccination status (including LAIV uptake) will be determined from the primary care and SIRS database. The primary outcome will be influenza-positive real-time PCR tests carried out in sentinel general practices and other healthcare settings. Secondary outcomes include influenza-like illness and asthma-related general practice consultations, hospitalisations and death. An instrumental variable analysis will be carried out to account for confounding. Self-controlled study designs will be used to estimate the risk of adverse events associated with influenza vaccination.ETHICS AND DISSEMINATION: We obtained approval from the National Research Ethics Service Committee, West Midlands-Edgbaston. The study findings will be presented at international conferences and published in peer-reviewed journals.TRIAL REGISTRATION NUMBER: ISRCTN88072400; Pre-results.",
keywords = "live vaccines, attenuated vaccines, inactivated vaccines, influenza, vaccination, seasonal, effectiveness, safety",
author = "Simpson, {Colin R} and Lone, {Nazir I} and Kimberley Kavanagh and Chris Robertson and Jim McMenamin and {von Wissmann}, Beatrix and Eleftheria Vasileiou and Chris Butler and Ritchie, {Lewis D} and Rory Gunson and J{\"u}rgen Schwarze and Aziz Sheikh",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.",
year = "2017",
month = "2",
day = "1",
doi = "10.1136/bmjopen-2016-014200",
language = "English",
volume = "7",
journal = "BMJ Open",
issn = "2044-6055",
number = "2",

}

Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination : protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. / Simpson, Colin R; Lone, Nazir I; Kavanagh, Kimberley; Robertson, Chris; McMenamin, Jim; von Wissmann, Beatrix; Vasileiou, Eleftheria; Butler, Chris; Ritchie, Lewis D; Gunson, Rory; Schwarze, Jürgen; Sheikh, Aziz.

In: BMJ Open, Vol. 7, No. 2, e014200, 01.02.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination

T2 - BMJ Open

AU - Simpson, Colin R

AU - Lone, Nazir I

AU - Kavanagh, Kimberley

AU - Robertson, Chris

AU - McMenamin, Jim

AU - von Wissmann, Beatrix

AU - Vasileiou, Eleftheria

AU - Butler, Chris

AU - Ritchie, Lewis D

AU - Gunson, Rory

AU - Schwarze, Jürgen

AU - Sheikh, Aziz

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - INTRODUCTION: Seasonal (inactivated) influenza vaccination is recommended for all individuals aged 65+ and in individuals under 65 who are at an increased risk of complications of influenza infection, for example, people with asthma. Live attenuated influenza vaccine (LAIV) was recommended for children as they are thought to be responsible for much of the transmission of influenza to the populations at risk of serious complications from influenza. A phased roll-out of the LAIV pilot programme began in 2013/2014. There is limited evidence for vaccine effectiveness (VE) in the populations targeted for influenza vaccination. The aim of this study is to examine the safety and effectiveness of the live attenuated seasonal influenza vaccine programme in children and the inactivated seasonal influenza vaccination programme among different age and at-risk groups of people.METHODS AND ANALYSIS: Test negative and cohort study designs will be used to estimate VE. A primary care database covering 1.25 million people in Scotland for the period 2000/2001 to 2015/2016 will be linked to the Scottish Immunisation Recall Service (SIRS), Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register. Vaccination status (including LAIV uptake) will be determined from the primary care and SIRS database. The primary outcome will be influenza-positive real-time PCR tests carried out in sentinel general practices and other healthcare settings. Secondary outcomes include influenza-like illness and asthma-related general practice consultations, hospitalisations and death. An instrumental variable analysis will be carried out to account for confounding. Self-controlled study designs will be used to estimate the risk of adverse events associated with influenza vaccination.ETHICS AND DISSEMINATION: We obtained approval from the National Research Ethics Service Committee, West Midlands-Edgbaston. The study findings will be presented at international conferences and published in peer-reviewed journals.TRIAL REGISTRATION NUMBER: ISRCTN88072400; Pre-results.

AB - INTRODUCTION: Seasonal (inactivated) influenza vaccination is recommended for all individuals aged 65+ and in individuals under 65 who are at an increased risk of complications of influenza infection, for example, people with asthma. Live attenuated influenza vaccine (LAIV) was recommended for children as they are thought to be responsible for much of the transmission of influenza to the populations at risk of serious complications from influenza. A phased roll-out of the LAIV pilot programme began in 2013/2014. There is limited evidence for vaccine effectiveness (VE) in the populations targeted for influenza vaccination. The aim of this study is to examine the safety and effectiveness of the live attenuated seasonal influenza vaccine programme in children and the inactivated seasonal influenza vaccination programme among different age and at-risk groups of people.METHODS AND ANALYSIS: Test negative and cohort study designs will be used to estimate VE. A primary care database covering 1.25 million people in Scotland for the period 2000/2001 to 2015/2016 will be linked to the Scottish Immunisation Recall Service (SIRS), Health Protection Scotland virology database, admissions to Scottish hospitals and the Scottish death register. Vaccination status (including LAIV uptake) will be determined from the primary care and SIRS database. The primary outcome will be influenza-positive real-time PCR tests carried out in sentinel general practices and other healthcare settings. Secondary outcomes include influenza-like illness and asthma-related general practice consultations, hospitalisations and death. An instrumental variable analysis will be carried out to account for confounding. Self-controlled study designs will be used to estimate the risk of adverse events associated with influenza vaccination.ETHICS AND DISSEMINATION: We obtained approval from the National Research Ethics Service Committee, West Midlands-Edgbaston. The study findings will be presented at international conferences and published in peer-reviewed journals.TRIAL REGISTRATION NUMBER: ISRCTN88072400; Pre-results.

KW - live vaccines

KW - attenuated vaccines

KW - inactivated vaccines

KW - influenza

KW - vaccination

KW - seasonal

KW - effectiveness

KW - safety

UR - http://bmjopen.bmj.com/

U2 - 10.1136/bmjopen-2016-014200

DO - 10.1136/bmjopen-2016-014200

M3 - Article

VL - 7

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 2

M1 - e014200

ER -